GlassScriptPhysician profile
Ryanne Clarke
NPI 1770911406
$122,579.62
in general payments reported to CMS, 2019-2025
25 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,942 · 2022: $14K · 2023: $24K · 2024: $41K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Travel and Lodging: $27K · Food and Beverage: $8,320 · Consulting Fee: $5,690 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,038.50 |
| Travel and Lodging | $26,610.89 |
| Food and Beverage | $8,319.78 |
| Consulting Fee | $5,690.00 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $117,150.89 | 2021-2025 | Biktarvy, Descovy, Yeztugo |
| Viiv Healthcare Company | $2,212.11 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $431.97 | 2021-2025 | Pifeltro, Delstrigo, Isentress |
| Abbvie INC. | $300.25 | 2021-2025 | |
| Abbott Laboratories | $290.48 | 2022-2025 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $256.60 | 2021-2023 | Symtuza |
| Novo Nordisk INC | $247.54 | 2022-2024 | Wegovy |
| Dexcom, INC. | $245.53 | 2021-2023 | Dexcom G7 Gss (161) |
| Lilly USA, LLC | $161.59 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $147.28 | 2024-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $141.59 | 2023 | |
| Dermavant Sciences, INC. | $124.99 | 2023 | Vtama |
| Xeris Pharmaceuticals, INC. | $121.87 | 2023 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2024 | Dupixent |
| Agile Therapeutics, INC. | $111.38 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.06 | 2025 | |
| Pfizer INC. | $78.90 | 2022-2025 | |
| Boston Scientific Corporation | $75.29 | 2023 | |
| Theratechnologies INC. | $73.36 | 2021-2025 | Trogarzo, Egrifta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.64 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $38.25 | 2022-2023 | Abilify Maintena |
| Idorsia Pharmaceuticals US INC | $35.58 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $26.82 | 2021 | |
| Hologic Sales and Service, LLC | $23.46 | 2024 | Aptima |
| Emd Serono, INC. | $16.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryanne Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.